News

Thirty-Six Month Follow Data Demonstrate Long-Term Effectiveness of AEGEA Medical’s Adaptive Vapor Ablation Technology

-

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, has announced that 36-month follow-up data from a prospective, multicenter, pivotal study of its AEGEA Vapor System were presented at the AAGL Global Conference on Minimally Invasive Gynecologic Surgery in Las Vegas on November 13. The data showed that the AEGEA Vapor System is a safe, effective and minimally invasive option

...Read more

AEGEA Medical Secures $17 Million in Financing

-

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, announced that it has raised $17 million in financing led by Solas BioVentures and its affiliates. The proceeds will be used to fund AEGEA’s prospective, multi center Post-Ablation Cavity Access (PACE II) study to evaluate uterine cavity access and the possibility of minimally invasive interventions

...Read more

AEGEA Medical Begins Enrollment in the PACE II Clinical Trial of Uterine Cavity Access More Than Three Years Following Vapor Endometrial Ablation

-

AEGEA Medical, Inc. has announced the commencement of the Post-Ablation Cavity Evaluation (PACE II) clinical study in women who previously underwent endometrial ablation as part of AEGEA’s pivotal trial of the company’s patented Adaptive Vapor Ablation technology. The multi-center observational study, which is being conducted at seven sites across the U.S. in up to 50 women, is designed to assess uterine cavity access as well as the feasibility of diagnostic and therapeutic interventions

...Read more

Twelve-Month Pivotal Data Supporting AEGEA Medical’s Adaptive Vapor Ablation Technology Published in the Journal of Minimally Invasive Gynecology (JMIG)

-

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, has announced that results from a 12-month prospective, multicenter, pivotal study of its AEGEA Vapor System were published in the peer-reviewed Journal of Minimally Invasive Gynecology

...Read more

AEGEA Medical Completes Enrollment in the PACE II Clinical Trial

-

AEGEA Medical announced it has completed enrollment in the Post-Ablation Cavity Evaluation (PACE II) clinical study in women who previously underwent endometrial ablation as part of a pivotal trial of AEGEA’s Adaptive Vapor Ablation technology. The multi-center observational study enrolled 50 women at seven sites across the U.S.

...Read more

AEGEA Medical Secures $40 million Financing

-

AEGEA Medical Inc. (“AEGEA”), a privately held medical technology company in the women’s health space focused on the development of its patented Adaptive Vapor Ablation technology for endometrial ablation, today announced it has closed on a $30 million financing with Perceptive Advisors (“Perceptive”). In connection with the financing

...Read more

AEGEA Medical Announces U.S. FDA Approval of the AEGEA Vapor System(TM) with Adaptive Vapor Ablation for the Treatment of Menorrhagia

-

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, today announced U.S. FDA approval of the AEGEA Vapor System as a new treatment option for menorrhagia. The AEGEA Vapor System is the first endometrial ablation system specifically designed for use in

...Read more


Important Safety Information:

The Mara Water Vapor Ablation System is indicated to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. Pregnancy following the Mara procedure can be dangerous. The Mara procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Mara Water Vapor Ablation System. Please refer to the device labeling for a detailed discussion of the device’s intended use, relevant warnings, precautions, side effects, and contraindications.